Hagaziekenhuis

The Hague, South Holland 2545AA

2 studies enrolling now · 7 studies all time

What they study most

BRAF V600E-mutant Metastatic Colorectal Cancer, Cancer, Castration-resistant Prostate Cancer, Immune Thrombocytopenic Purpura (ITP), Metastatic Breast Cancer, Multiple Myeloma, Prostate Cancer Metastatic

Studies at this site

• A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia — Recruiting now
• A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia — Recruiting now
• Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer — Running, not enrolling
• Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant — Running, not enrolling
• HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Stopped early
• Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) — Completed
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed